InterMune's Esbriet gets OK from EU CHMP: launch expected 3Q11
This article was originally published in Scrip
Executive Summary
InterMune's Esbriet (pirfenidone) received a positive opinion by the EU's Committee for Medicinal Products for Human Use (CHMP), the first European approval for any drug to treat mild-to-moderate idiopathic pulmonary fibrosis (IPF). In a conference call, the company CEO and President, Dan Welch, said that the company anticipated a price band for the product of $40,000-45,000 and that the product would be launched in the five largest European national markets – Germany, France, Italy, Spain and the UK – by mid 2012, with the first launch in Germany scheduled for the third quarter of 2011.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.